Opioid properties of nitrous oxide and ketamine contribute to their antidepressant actions

Author (Sole): Prof Mark A Gillman (Emeritus CEO SA brain Research Institute)

Academic Qualifications: BDS DSc

Contact Address:
6 Campbell St
Waverley 2090
Johannesburg
South Africa

Tel: +27117862912
Fax: NIL

Email: mag@iafrica.com
Significance:
Lately there has been an uptick in interest of a field that has lain dormant for 30 years i.e examining the psychotropic actions of non-anaesthetic concentrations of nitrous oxide. In the earlier work, nitrous oxide was shown to be an opioid agonist but in common with the classical opioid morphine, to interact with other neurotransmitter systems as well. Although there is little doubt that nitrous oxide at subanaesthetic doses interacts with the opioid system, the recent entrants into the field, do not seem to accept the possibility of opioid system involvement in the psychotropic actions of nitrous oxide. Instead, they suggest that the psychotropic actions are mediated, like ketamine, mainly by the NMDA system alone. There is now definitive evidence from research in animals and man that the antidepressant properties of ketamine are mediated, at least partially, by the opioid system. It is therefore important to emphasise the possibility that like ketamine, the antidepressant actions of subanaesthetic N₂O is mediated by other neurotransmitters apart from N-methyl-D-aspartate system. My letter presents some of the extant evidence that the gas exerts some of its actions via interactions with the opioid system, as does ketamine.
I welcome the paper by Kamboj and colleagues (2021), which continues the recent upsurge of research into the psychotropic properties of non-anaesthetic nitrous oxide (N₂O).

However, I would like to comment on a number of matters raised in their paper (Kamboj et al., 2021).

First, I disagree with the notion, held by these workers and most current investigators in the field that the psychotropic properties of ketamine and subanaesthetic N₂O are mainly produced by N-Methyl-D-Aspartate receptor (NMDAR) antagonism (for references see Kamboj et al., 2021). While there is evidence that both N₂O and ketamine interact with the NMDAR, there is compelling evidence that both substances also interact with opioid receptors (Emmanouil and Quock 2007, Sarton, et al. 2001, Smith et al., 1987, Matussek, 2003 (for additional references see Gillman, 2019a;b) to exert their psychotropic actions. Among the most convincing of these is that blockade of opioid receptors interferes with the antidepressant action of ketamine in animals (Klein et al., 2019) and man (Williams, et al., 2018).

Further, the NMDAR receptor activity of N₂O occurs not at subanaesthetic but predominantly at anaesthetic concentrations (Jevtović-Todorović et al., 1998), making it unlikely that the psychotropic actions observed at subanaesthetic concentrations are mediated by NMDAR. Another factor, is that memantine, a NMDAR blocker, has little antidepressant or opioid activity (Gillman, 2019b). It is therefore doubtful that the antidepressant actions of ketamine and N₂O are mainly due to NMADR blockade (Gillman, 2019b), because if this were correct then memantine, which lacks opioid activity, would also probably have antidepressant properties.

It is worth noting here, that in the 19th Century, opium was used to ameliorate depression and more recently, buprenorphine, has been used for the same purpose (for references see...
Further, upregulation of opioid receptors has been observed in the post-mortem brains of subjects who have committed suicide. (Matussek, 2003). Both these facts give more support to opioid involvement in the antidepressant activity of subanaesthetic N₂O and ketamine (Matussek, 2003; Gillman, 2019a;b).

Moreover, in human subjects, high impulsivity has been positively correlated with high opioid receptor concentrations in the brain, particularly in regions important for motivational behaviour and substance abuse (Love et al., 2009). Significantly, Kamboj et al. (2021) observed a positive correlation between liking for N₂O and impulsivity. Since subanaesthetic N₂O and ketamine have opioid properties (Emmanouil and Quock 2007, Sarton, et al., 2001, Smith et al., 1987, Matussek, 2003; for additional references see Gillman, 2019a,b) these observations (Kamboj et al. 2020) are more likely to have been due to opioid activity rather than NMDAR blockade.

Second, the assumption that the antidepressant actions of subanaesthetic N₂O was discovered in 2015 is simply wrong. Gillman and Lichtigfeld observed the antidepressant action of subanaesthetic N₂O in 1982, in alcoholic and later in non-alcoholic subjects in 1985 (see Matussek, 2003; Gillman, 2019a for references).

Third, these researchers (Kamboj et al., 2021) state N₂O ‘also been tested as a treatment for acute alcohol withdrawal’. This may give the wrong impression. Not only has it been tested (Gillman et al., 2008) but it has been widely and successfully used to treat alcoholic withdrawal states in South Africa and Finland ‘....‘it is a recognised’ by the health authorities as a ‘treatment for substance abuse withdrawal states’ (Gillman et al., 2008).
Finally, these workers noted possible blinding problems with their study (Kamboj et al., 2021). To overcome the difficulty of blinding, when using a rapidly acting agent like N₂O, Lichtigfeld and I developed a double-blind method used in 2002 and 2004 (see references in Gillman et al., 2008). The latter method enabled us to test double-blind, active diazepine tablets plus placebo gas against placebo tablets and active gas. Consequently, we were able to show double-blind, that N₂O is better than diazepam for alcohol withdrawal states. Perhaps these investigators (Kamboj et al., 2021) and others could use a similar or modification of this method so they can ensure blinding in future investigations of the psychotropic properties of subanaesthetic N₂O?

**Funding:**

Nil

**Acknowledgements**

Luis Gillman for assistance with manuscript submission.

**Statement of Interest**

I have been researching the psychotropic actions of non-anaesthetic nitrous oxide for over 40 years. Since 2003, I have been the medical adviser to Sedatek a company that supplies equipment for administering nitrous oxide/oxygen for conscious sedation in South Africa. I own no shares in Sedatek.
References

Emmanouil DE, Quock RM (2007). Advances in understanding the actions of nitrous oxide. *Anesthesia Progress* 54, 9–18.

Gillman MA. (2019a). Mini-Review: A brief history of nitrous oxide (N2O) use in neuropsychiatry. *Current Drug Research Reviews* 11, 12–20. doi:10.2174/1874473711666181008163107.

Gillman MA. (2019b). Words of caution on using fixed 50% concentrations of nitrous oxide in psychiatry. *Journal of Clinical Psychopharmacology* 39, 421–422. DOI: 10.1097/jcp.0000000000001067.

Gillman MA, Lichtigfeld FJ, Young T (2008). Psychotropic analgesic nitrous oxide for alcoholic withdrawal states. (Review) *Cochrane Library, Systematic Review (Issue 4).*

Kamboj SK, Zhao H, Troebinger L, Piazza G, Cawley E, Hennessy V, Iskandar G, Ravi K, Das RK (2021). Rewarding subjective effects of the NMDAR antagonist, nitrous oxide (‘laughing gas’) are moderated by impulsivity and depressive symptoms in healthy volunteers. *International Journal of Neuropsychopharmacology* 2021 Mar 1:pyab009. DOI: 10.1093/ijnp/pyab009. Online ahead of print. PMID: 33667308.

Klein ME, J Chandra J, Sheriff S, Malinow R. (2020). Opioid system is necessary but not sufficient for anti-depressive actions of ketamine in rodents. *Proceedings of the National Academy of Sciences (USA)* 117, 2656–2662.

Matussek N (2003). Opioid system in depression. *International Journal of Neuropsychopharmacology* 6:443. DOI:10.1017/S1461145703003808. PMID: 14604460.

Sarton E1, Teppema LJ, Olievier C, Nieuwenhuijs D, Matthes HW, Kieffer BL, Dahan A (2001). The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception. *Anesthesia & Analgesia* 93, 1495-500. DOI: 10.1097/00000539-200112000-00031. PMID: 11726430.
Smith DJ, Bouchal RL, DeSanctis CA, Monroe PJ, Amedro JB, Perrotti JM, Crisp T (1987). Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. *Neuropharmacology* 9,1253-60. DOI:10.1016/0028-3908(87)90084-0. PMID: 2823161.

Jevtović-Todorović V, Todorović SM, Mennerick S, Powell S, Dikranian K, Benshoff N, Zorumski CF, Olney JW (1998). Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. *Nature Medicine* 4,460-3. DOI: 10.1038/nm0498-460. PMID: 9546794.

Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., & Schatzberg, A. F. (2018). Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. *American Journal of Psychiatry* 175,1205–1215. https://doi.org/10.1176/appi.ajp.2018.18020138